Denosumab missed dose — GPhC CRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: A — Advise prompt prescriber review because delayed doses can increase fracture risk
Denosumab discontinuation or substantial delay can be associated with rebound bone turnover and increased vertebral fracture risk. The patient needs prompt review to arrange the injection or an alternative strategy. Calcium and vitamin D may be important but do not replace antiresorptive treatment. The pharmacist should escalate rather than reassure falsely.
Reference: BNF; MHRA Drug Safety Update